The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study
Abstract
Purpose: Venous thromboembolism (VTE) is a well-recognized complication of cancer. Laboratory parameters might be useful to assess the VTE risk in patients with cancer. The aim of this study was to investigate D-dimer and prothrombin fragment 1 + 2 (F 1 + 2), which reflect activation of blood coagulation and fibrinolysis, for prediction of cancer-associated VTE. Patients and Methods: In a prospective, observational, cohort study of 821 patients with newly diagnosed cancer or progression of disease who did not recently receive chemotherapy, radiotherapy, or surgery were enrolled and followed for a median of 501 days (interquartile range, 255 to 731 days). The malignancies in these patients were as follows: breast (n = 132), lung (n = 119), stomach (n = 35), lower gastrointestinal tract (n = 106), pancreas (n = 46), kidney (n = 22), and prostate (n = 101) cancers; high-grade glioma (n = 102); malignant lymphoma (n = 94); multiple myeloma (n = 17); and other tumor types (n = 47). The study end point was occurrence of objectively confirmed symptomatic or fatal VTE. Results: VTE occurred in 62 patients (7.6%). The cutoff level for elevated D-dimer and elevated F 1 + 2 was set at the 75th percentile of the total study population. In multivariable analysis that included elevated D-dimer, elevated F 1 + 2, age, sex, surgery, chemotherapy, and radiotherapy, the hazard ratios (HRs) of VTE in patients with elevated D-dimer (HR, 1.8; 95% CI, 1.0 to 3.2; P = .048) and elevated F 1 + 2 (HR, 2.0; 95% CI, 1.2 to 3.6; P = .015) were statistically significantly increased. The cumulative probability of developing VTE after 6 months was highest in patients with both elevated D-dimer and elevated F 1 + 2 (15.2%) compared with patients with nonelevated D-dimer and nonelevated F 1 + 2 (5.0%; P < .001). Conclusion: High D-dimer and F 1 + 2 levels independently predict occurrence of VTE in patients with cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Prevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
A note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
Development and validation of a predictive model for chemotherapy-associated thrombosis
Khorana, A. A., Kuderer, N. M., Culakova, E., Lyman, G. H., & Francis, C. W. (2008) · Blood · doi:10.1182/blood-2007-10-116327 · Cited by 2,217
Prandoni, P., Lensing, A. W. A., Piccioli, A., Bernardi, E., Simioni, P., Girolami, B., Marchiori, A., Sabbion, P., Prins, M. H., Noventa, F., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0108 · Cited by 1,863
Prognosis of Cancers Associated with Venous Thromboembolism
Sørensen, H. T., Mellemkjær, L., Olsen, J. H., & Baron, J. A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432504 · Cited by 1,628
Incidence of Venous Thromboembolism and Its Effect on Survival Among Patients With Common Cancers
Chew, H. K., Wun, T., Harvey, D. J., Zhou, H., & White, R. H. R. (2006) · Archives of Internal Medicine · doi:10.1001/.458 · Cited by 1,321
Activation of blood coagulation in cancer: Trousseau's syndrome revisited
Rickles, F., & Edwards, R. (1983) · Blood · doi:10.1182/blood.v62.1.14.14 · Cited by 749
BLOM, J. W., VANDERSCHOOT, J. P. M., OOSTINDIËR, M. J., OSANTO, S., VAN DER MEER, F. J. M., & ROSENDAAL, F. R. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01804.x · Cited by 692
d -Dimer Testing to Determine the Duration of Anticoagulation Therapy
Palareti, G., Cosmi, B., Legnani, C., Tosetto, A., Brusi, C., Iorio, A., Pengo, V., Ghirarduzzi, A., Pattacini, C., Testa, S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054444 · Cited by 622
Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells
Palumbo, J. S., Kombrinck, K. W., Drew, A. F., Grimes, T. S., Kiser, J. H., Degen, J. L., & Bugge, T. H. (2000) · Blood · doi:10.1182/blood.v96.10.3302 · Cited by 605
Risk factors for chemotherapy‐associated venous thromboembolism in a prospective observational study
Khorana, A. A., Francis, C. W., Culakova, E., & Lyman, G. H. (2005) · Cancer · doi:10.1002/cncr.21496 · Cited by 565
Cancer and venous thromboembolism
Prandoni, P., Falanga, A., & Piccioli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70207-2 · Cited by 540
Ay, C., Simanek, R., Vormittag, R., Dunkler, D., Alguel, G., Koder, S., Kornek, G., Marosi, C., Wagner, O., Zielinski, C., et al. (2008) · Blood · doi:10.1182/blood-2008-02-142422 · Cited by 422
Self-citationVenous Thromboembolism in Patients With Colorectal Cancer: Incidence and Effect on Survival
Alcalay, A., Wun, T., Khatri, V., Chew, H. K., Harvey, D., Zhou, H., & White, R. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.2150 · Cited by 365
D-Dimer Levels and Risk of Recurrent Venous Thromboembolism
Eichinger, S. (2003) · JAMA · doi:10.1001/jama.290.8.1071 · Cited by 327
Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer
KHORANA, A. A., FRANCIS, C. W., MENZIES, K. E., WANG, J.-G., HYRIEN, O., HATHCOCK, J., MACKMAN, N., & TAUBMAN, M. B. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03156.x · Cited by 309
Legnani, C., Cosmi, B., Guazzaloca, G., Pancani, C., Coccheri, S., & Palareti, G. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1612936 · Cited by 291
Incidence of Venous Thromboembolism and the Impact on Survival in Breast Cancer Patients
Chew, H. K., Wun, T., Harvey, D. J., Zhou, H., & White, R. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.4393 · Cited by 278
Palareti, G., Legnani, C., Cosmi, B., Valdré, L., Lunghi, B., Bernardi, F., & Coccheri, S. (2003) · Circulation · doi:10.1161/01.cir.0000079162.69615.0f · Cited by 276
Fibrin fragment D-dimer and the risk of future venous thrombosis
Cushman, M., Folsom, A. R., Wang, L., Aleksic, N., Rosamond, W. D., Tracy, R. P., & Heckbert, S. R. (2003) · Blood · doi:10.1182/blood-2002-05-1416 · Cited by 231
Kuderer, N. M., Khorana, A. A., Lyman, G. H., & Francis, C. W. (2007) · Cancer · doi:10.1002/cncr.22892 · Cited by 212
Risk factors for venous thromboembolic events in cancer patients
Kröger, K., Weiland, D., Ose, C., Neumann, N., Weiss, S., Hirsch, C., Urbanski, K., Seeber, S., & Scheulen, M. E. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj068 · Cited by 212
Cancer and thrombosis: from molecular mechanisms to clinical presentations
BULLER, H. R., VAN DOORMAAL, F. F., VAN SLUIS, G. L., & KAMPHUISEN, P. W. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02497.x · Cited by 177
Help me, Doctor! My D-dimer is raised
Lippi, G., Franchini, M., Targher, G., & Favaloro, E. J. (2008) · Annals of Medicine · doi:10.1080/07853890802161015 · Cited by 94
The role of fibrin in tumor metastasis
Costantini, V., & Zacharski, L. R. (1992) · Cancer and Metastasis Reviews · doi:10.1007/bf01307183 · Cited by 89
Elevated Levels of Prothrombin Fragment 1 + 2 Indicate High Risk of Thrombosis
Ota, S., Wada, H., Abe, Y., Yamada, E., Sakaguchi, A., Nishioka, J., Hatada, T., Ishikura, K., Yamada, N., Sudo, A., et al. (2007) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029607309176 · Cited by 76
Cosmi, B., Legnani, C., Cini, M., Guazzaloca, G., & Palareti, G. (2005) · PubMed · Cited by 47
Prothrombin Fragment F1+2 Is not Predictive for Recurrent Venous Thromboembolism
Kyrle, P. A., Eichinger, S., Pabinger, I., Stümpflen, A., Hirschl, M., Bialonczyk, C., Schneider, B., Mannhalter, C., Melichart, M., Traxler, G., et al. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1656062 · Cited by 26
Self-citationClotting activation after oral anticoagulant therapy discontinuation
Poli, D., Antonucci, E., Cecchi, E., Betti, I., Lapini, I., Gazzini, A., Abbate, R., Gensini, G. F., & Prisco, D. (2004) · Blood Coagulation & Fibrinolysis · doi:10.1097/00001721-200404000-00004 · Cited by 10
Cited by
Epidemiology of cancer-associated venous thrombosis
Timp, J. F., Braekkan, S. K., Versteeg, H. H., & Cannegieter, S. C. (2013) · Blood · doi:10.1182/blood-2013-04-460121 · Cited by 1,205
Prediction of venous thromboembolism in cancer patients
Ay, C., Dunkler, D., Marosi, C., Chiriac, A.-L., Vormittag, R., Simanek, R., Quehenberger, P., Zielinski, C., & Pabinger, I. (2010) · Blood · doi:10.1182/blood-2010-02-270116 · Cited by 772
Self-citationRisk of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis
Horsted, F., West, J., & Grainge, M. J. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001275 · Cited by 565
Cancer-associated venous thromboembolism: Burden, mechanisms, and management
Ay, C., Pabinger, I., & Cohen, A. T. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-08-0615 · Cited by 496
Self-citationCurrent concepts and management of glioblastoma
Preusser, M., de Ribaupierre, S., Wöhrer, A., Erridge, S. C., Hegi, M., Weller, M., & Stupp, R. (2011) · Annals of Neurology · doi:10.1002/ana.22425 · Cited by 461
Metadata
- Authors
- Ay, C., Vormittag, R., Dunkler, D., Simanek, R., Chiriac, A.-L., Drach, J., Quehenberger, P., Wagner, O., Zielinski, C., & Pabinger, I.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-09-01
- Volume
- 27
- Issue
- 25
- Pages
- 4124-4129
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2013996375
- Cited by
- 422
- References
- 30
- FWCI
- 16.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.